Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
AssigneeLutonix, Inc.
InventorLixiao Wang
Life of this patent
Estimating the term…
Abstract
Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues).
Claims31
A method for treating at least one of asthma, chronic obstructive pulmonary disease, and chronic sinusitis in a mammal comprising:
- administering a pharmaceutical formulation comprising an effective amount of a drug and an additive to said mammal via a balloon catheter into a body passage of the respiratory or sinus system, wherein said drug is chosen from rapamycin and paclitaxel.
2-3. (canceled)
(canceled)
12-13. (canceled)
15-22. (canceled)
24-28. (canceled)
30-32. (canceled)
34-38. (canceled)
41-91. (canceled)
A device sized and configured for insertion into a passage of a respiratory system, the device comprising a layer overlying an exterior surface of the device, the layer comprising a water insoluble drug for the treatment of the respiratory system and an additive that enhances absorption of the drug into tissue of the respiratory system, wherein:
- the device is a balloon catheter;
- the water insoluble drug is chosen from paclitaxel and rapamycin;
- and
- the additive is chosen from from PEG-fatty acids and PEG-fatty acid mono and diesters, polyethylene glycol glycerol fatty acid esters, alcohol-oil transesterification products, polyglyceryl fatty acids, propylene glycol fatty acid esters, sterol and derivatives thereof, polyethylene glycol sorbitan fatty acid esters, polyethylene glycol alkyl ethers, sugars and derivatives thereof, polyethylene glycol alkyl phenols, polyoxyethylene-polyoxypropylene block copolymers, sorbitan fatty acid esters, fat-soluble vitamins and salts thereof, water-soluble vitamins and amphiphilic derivatives thereof, amino acid and salts thereof, oligopeptides, peptides and proteins, and organic acids and esters and anhydrides thereof.
(canceled)
96-100. (canceled)
A method for treating a respiratory system comprising:
- inserting a balloon catheter comprising a coating layer into an airway, wherein the coating layer comprises a drug and an additive, wherein:
- the drug is chosen from paclitaxel and rapamycin;
- and
- the additive is chosen from from PEG-fatty acids and PEG-fatty acid mono and diesters, polyethylene glycol glycerol fatty acid esters, alcohol-oil transesterification products, polyglyceryl fatty acids, propylene glycol fatty acid esters, sterol and derivatives thereof, polyethylene glycol sorbitan fatty acid esters, polyethylene glycol alkyl ethers, sugars and derivatives thereof, polyethylene glycol alkyl phenols, polyoxyethylene-polyoxypropylene block copolymers, sorbitan fatty acid esters, fat-soluble vitamins and salts thereof, water-soluble vitamins and amphiphilic derivatives thereof, amino acid and salts thereof, oligopeptides, peptides and proteins, and organic acids and esters and anhydrides thereof;
- inflating the balloon catheter and releasing the drug to a wall of the airway;
- deflating the balloon;
- and
- withdrawing the balloon catheter from the airway.
103-109. (canceled)
Dependencies are inferred from the claim text.